Cyclophosphamide serves as an alkylating chemotherapeutic agent frequently administered as a primary first-line treatment for hematological tumors in preadolescent female patients. Although clinically effective against malignant diseases, cyclophosphamide is recognized to cause significant cellular damage to developing oocytes. Human amniotic mesenchymal stem cells possess antioxidant and anti-apoptotic properties. Consequently, extracellular vesicles derived from these stem cells were investigated for their antioxidant capacity to alleviate cyclophosphamide-induced oxidative stress and preserve oocyte quality in experimental models.
To examine these protective effects systematically, researchers utilized prepubertal female C57BL/6J mice aged three to six weeks. The in vivo protocol involved administering intraperitoneal injections of cyclophosphamide to the test subjects, while control animals received equivalent intraperitoneal injections of normal saline. After the animals reached sexual maturity, cumulus oocyte complexes were harvested from the female mice and subjected to in vitro maturation and in vitro fertilization to evaluate the direct impact of chemotherapy exposure on oocyte quality.
In an accompanying in vitro model, cumulus oocyte complexes isolated from preadolescent mice were maintained in culture medium supplemented with 4-hydroxycyclophosphamide at a concentration of 1 micromolar. Because 4-hydroxycyclophosphamide represents an active intermediate metabolite of cyclophosphamide, this approach permitted the direct modeling of chemotherapeutic stress under defined laboratory conditions. Investigators subsequently evaluated the specific cytoprotective mechanisms of human amniotic mesenchymal stem cell-derived extracellular vesicles on these chemically injured cells.
The experimental results showed that direct intraperitoneal injection of cyclophosphamide altered reproductive outcomes in the animal model. Specifically, cyclophosphamide administration reduced the total number of viable mouse oocytes retrieved following ovulation induction. Furthermore, cyclophosphamide treatment significantly decreased the mitochondrial membrane potential of in vitro matured oocytes (p < 0.05) while causing a statistically significant elevation in intracellular reactive oxygen species content (p < 0.05).
Direct in vitro exposure to 1 micromolar 4-hydroxycyclophosphamide also induced substantial physiological impairment in the cultured oocytes. The metabolite significantly reduced mitochondrial membrane potential (p < 0.05) and significantly lowered cytoplasmic maturity (p < 0.05). Additionally, treatment with 4-hydroxycyclophosphamide produced a statistically significant increase in intracellular superoxide anion levels (p < 0.05), confirming that cyclophosphamide metabolites trigger severe oxidative stress and compromise cytoplasmic maturation.
Assessment of subsequent embryonic development revealed further chemotherapeutic disruptions. Following cyclophosphamide administration, the embryonic cleavage rate displayed an observable downward trend; however, this reduction did not achieve statistical significance (p = 0.1741). In contrast, the subsequent rate of blastocyst formation from treated oocytes exhibited a statistically significant decrease (p < 0.05), demonstrating that chemotherapeutic exposure impairs downstream developmental competence.
Treatment with human amniotic mesenchymal stem cell-derived extracellular vesicles counteracted these chemotherapeutic injuries across both experimental settings. The extracellular vesicles successfully mitigated intracellular oxidative stress induced either by intraperitoneal cyclophosphamide injection or by in vitro 4-hydroxycyclophosphamide exposure. Importantly, vesicle intervention restored developmental potential, yielding a statistically significant improvement in the blastocyst formation rate of the treated oocytes (p < 0.05).
Molecular analysis confirmed that human amniotic mesenchymal stem cell-derived extracellular vesicles down-regulated the overexpression of stress-associated genes in vitro. Vesicle supplementation significantly reduced the elevated expression levels of KLF4, P53, and P21 caused by cyclophosphamide and 1 micromolar 4-hydroxycyclophosphamide (p < 0.05). The researchers concluded that cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide diminish oocyte quality and embryo development, while stem cell-derived extracellular vesicles preserve both cellular integrity and subsequent developmental viability.
Subject of Research: Human amniotic mesenchymal stem cell-derived extracellular vesicles preserving oocyte quality during cyclophosphamide chemotherapy
Article Title: Human amniotic mesenchymal stem cell-derived extracellular vesicles improve the maturation and developmental potential of oocytes cultured in vitro after cyclophosphamide treatment
Article References: Cheng, L., Feng, C., Qian, J., Wang, J., Ni, M., Guo, S., Wu, H., Yan, Z., Ning, S., Jiang, C., Qin, L., & Ma, X. (2026). Human amniotic mesenchymal stem cell-derived extracellular vesicles improve the maturation and developmental potential of oocytes cultured in vitro after cyclophosphamide treatment. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02345-x
Image Credits: AI Generated
DOI: 10.1186/s13048-026-02345-x
Keywords: cyclophosphamide, 4-hydroxycyclophosphamide, oocytes, in vitro maturation, extracellular vesicles, human amniotic mesenchymal stem cells, mitochondrial membrane potential, reactive oxygen species, superoxide anions, blastocyst formation, cumulus oocyte complexes, KLF4, P53, P21, C57BL/6J mice, chemotherapeutic stress
News Source: Nathaniel Bowman. (November 19, 2026). Stem Cell Extracellular Vesicles Protect Mouse Oocytes From Cyclophosphamide Chemotherapy Damage. Scienmag.



